Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1775 + FLAG in relapsed/refractory AML
NCT02791919Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- May 2017
- Primary completion
- May 2019
01
Overview
Phase 1, open-label trial of adavosertib in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Planned start May 2017; status: withdrawn.
02
Drugs
adavosertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02791919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02791919.